Identification of immunological predictors of COVID-19 clinical outcomes

识别 COVID-19 临床结果的免疫学预测因子

• 批准号: 10272303
• 负责人: Andrea Lisco
• 金额: $ 0.26万
• 依托单位: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10272303
• 关键词: 2019-nCoV; Biological; Blood Donations; Blood Screening; COVID-19; Clinical; Clinical Data; Collaborations; Disease; Gene Expression Profiling; Genetic; Goals; Immunologics; Individual; Infection; Integration Host Factors; Medical center; National Institute of Allergy and Infectious Disease; Outcome; Peripheral Blood Mononuclear Cell; Research Personnel; Serological; Severities; Specimen; biomarker identification; clinical predictors; comorbidity; genetic variant; human pathogen; human virome; novel; response

The extraordinarily wide spectrum of clinical manifestations associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, ranging from asymptomatic to fatal disease, represent an unexpected and unexplained clinical feature for an emerging highly contagious novel human pathogen. Host factors implicated in the innate or adaptive response to SARS-Cov2 as well as comorbidities or yet unidentified predictor are likely to be associated with such broad spectrum of clinical outcomes. In collaboration with a network of southern italian medical centers (Bari, Foggia, Caserta) we have collected de-identified clinical data and biological specimens from over 300 individuals with asymptomatic infection (as identified by SARS-COv2 serological screening for blood donation), mild, moderate, severe or critical COVID-19 diseases to analyze the genetic and immunological correlates of these clinical outcomes in a collaborative project with other NIAID intramural investigators.

与严重的急性呼吸道综合征2（SARS-COV-2）感染相关的临床表现非常广泛，范围从无症状到致命疾病，代表了出乎意料且无法解释的临床特征，对于出现的高度传染性的新型人类病原体。与SARS-COV2的先天或适应性反应有关的宿主因素以及合并症或未识别的预测因子可能与如此广泛的临床结果相关。 In collaboration with a network of southern italian medical centers (Bari, Foggia, Caserta) we have collected de-identified clinical data and biological specimens from over 300 individuals with asymptomatic infection (as identified by SARS-COv2 serological screening for blood donation), mild, moderate, severe or critical COVID-19 diseases to analyze the genetic and immunological correlates of these clinical outcomes in a collaborative project与其他NIAID壁内研究人员。